BioSIM 抗人 ANG2 x VEGFA 抗体 (法瑞西

BioSIM 抗人 ANG2 x VEGFA 双特异性抗体 (法瑞西单抗生物类似物) - 科研级

产品概述

BioSIM anti-Human ANG2 x VEGFA Bispecific Antibody 是一款高质量的双特异性抗体，针对血管生成素-2(ANG2)和血管内皮生长因子A(VEGFA)的人源化抗体，作为法瑞西单抗(Faricimab)的生物类似物，专为科研应用设计。该产品由InvivoCrown公司生产，货号SIM0474，规格为1mg。

产品特性

• 双特异性设计：同时靶向ANG2和VEGFA两种关键血管生成因子
• 人源化来源：降低免疫原性，更适合人体相关研究
• 高纯度：经过多步纯化工艺，包括Protein A或G色谱技术
• 无动物成分：在无动物成分的设施中生产，使用无蛋白细胞培养技术
• 严格质控：确保批次间一致性和可靠性

生物学背景与应用领域

ANG2和VEGFA是眼部血管疾病中的关键靶点，特别是在湿性年龄相关性黄斑变性(wAMD)和糖尿病性黄斑水肿(DME)的病理过程中发挥重要作用。这款双特异性抗体通过同时阻断这两条信号通路，可能提供更全面的治疗效果，是相关疾病机制研究和药物开发的重要工具。

科研应用

BioSIM抗人ANG2 x VEGFA抗体适用于多种实验研究：

• ELISA：用于检测样本中ANG2和VEGFA的浓度变化
• FACS：流式细胞术分析细胞表面抗原表达
• 功能性测定：评估抗体对血管生成相关功能的影响
• 体内研究：动物模型中的药效学和药代动力学研究

技术参数

储存与稳定性

为确保产品活性和稳定性，请遵循以下储存条件：

• 避免反复冻融：保持抗体稳定性
• 短期保存(1-2周)：4°C
• 中期保存(最长12个月)：-20°C
• 长期保存：-80°C

使用建议

建议在使用前离心收集管壁液体，确保抗体均匀。根据具体实验设计优化抗体浓度，通常工作浓度范围请参考相关文献或进行预实验确定。使用无菌技术操作，避免微生物污染。

订购信息

产品名称：BioSIM 抗人 ANG2 x VEGFA 抗体 (法瑞西单抗)，生物类似药，科研用途
产品货号：SIM0474-1mg
规格：1mg
供应商：InvivoCrown

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM Anti-Human ANG2 x VEGFA Bispecific Antibody (Faricimab Biosimilar) - Research Grade

Product Overview

BioSIM anti-Human ANG2 x VEGFA Bispecific Antibody is a high-quality bispecific antibody, a humanized antibody targeting Angiopoietin-2 (ANG2) and Vascular Endothelial Growth Factor A (VEGFA), developed as a biosimilar of Faricimab and specifically designed for research applications. This product is manufactured by InvivoCrown with catalog number SIM0474 and specification of 1mg.

Product Features

• Bispecific Design: Simultaneously targets two key angiogenic factors, ANG2 and VEGFA
• Humanized Source: Reduced immunogenicity, more suitable for human-related research
• High Purity: Purified through multiple steps, including Protein A or G chromatography
• Animal Component-Free: Produced in animal component-free facilities using protein-free cell culture technology
• Strict Quality Control: Ensures consistency and reliability between batches

Biological Background and Application Areas

ANG2 and VEGFA are key targets in ocular vascular diseases, playing particularly important roles in the pathological processes of Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME). This bispecific antibody may provide more comprehensive therapeutic effects by simultaneously blocking both signaling pathways, making it an important tool for disease mechanism research and drug development.

Research Applications

BioSIM anti-Human ANG2 x VEGFA antibody is suitable for various experimental studies:

• ELISA: For detecting concentration changes of ANG2 and VEGFA in samples
• FACS: Flow cytometry analysis of cell surface antigen expression
• Functional Assays: Evaluating the effects of the antibody on angiogenesis-related functions
• In Vivo Studies: Pharmacodynamic and pharmacokinetic studies in animal models

Technical Parameters

Storage and Stability

To maintain product activity and stability, please follow the following storage conditions:

• Avoid repeated freeze-thaw cycles: To maintain antibody stability
• Short-term storage (1-2 weeks): 4°C
• Medium-term storage (up to 12 months): -20°C
• Long-term storage: -80°C

Usage Recommendations

It is recommended to centrifuge before use to collect liquid from the tube wall and ensure uniform distribution of the antibody. Optimize antibody concentration based on specific experimental design; typically, the working concentration range should be determined by referring to relevant literature or conducting preliminary experiments. Use aseptic techniques during operation to avoid microbial contamination.

Ordering Information

Product Name: BioSIM Anti-Human ANG2 x VEGFA Antibody (Faricimab), Biosimilar, Research Use
Catalog Number: SIM0474-1mg
Specification: 1mg
Supplier: InvivoCrown

Note: The above information may change due to product optimization and upgrades. Please consult Yakeyin Company for specific details.